We recently reported that a combination of FDA-approved cancer drugs targeting poly (ADP-ribose) polymerase (PARP) enzymes with HDAC inhibitors effectively reactivates latent HIV infected cells (Figure 5) [151]. The gene discussed is PARP1; the disease is cancer.